- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02805348
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
April 2, 2019 updated by: Astellas Pharma Inc
Long-Term Specified Drug Use-Results Survey in Patients With Pre-dialysis Chronic Kidney Disease
The objective of this study is to assess the long-term safety and efficacy of bixalomer under post-marketed setting.
Study Overview
Study Type
Observational
Enrollment (Actual)
144
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan
- Site JP00006
-
Ehime, Japan
- Site JP00010
-
Fukuoka, Japan
- Site JP00012
-
Gifu, Japan
- Site JP00004
-
Ibaraki, Japan
- Site JP00001
-
Kagawa, Japan
- Site JP00009
-
Kanagawa, Japan
- Site JP00003
-
Kochi, Japan
- Site JP00011
-
Kumamoto, Japan
- Site JP00014
-
Nagasaki, Japan
- Site JP00013
-
Osaka, Japan
- Site JP00007
-
Shizuoka, Japan
- Site JP00005
-
Tochigi, Japan
- Site JP00002
-
Wakayama, Japan
- Site JP00008
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time
Description
Inclusion Criteria:
- Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chronic kidney disease
Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in the serum concentrations of phosphate
Time Frame: Baseline and up to Month 12
|
Baseline and up to Month 12
|
Change from baseline in the corrected serum concentrations of calcium
Time Frame: Baseline and up to Month 12
|
Baseline and up to Month 12
|
Change from baseline in the serum concentrations of intact parathyroid hormone
Time Frame: Baseline and up to Month 12
|
Baseline and up to Month 12
|
Safety assessed by incidence of adverse events
Time Frame: Up to Month 12
|
Up to Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
June 16, 2016
First Submitted That Met QC Criteria
June 16, 2016
First Posted (Estimate)
June 20, 2016
Study Record Updates
Last Update Posted (Actual)
April 3, 2019
Last Update Submitted That Met QC Criteria
April 2, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1585-MA-3052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Bixalomer
-
Astellas Pharma IncCompletedHealthy | Urine Phosphorus ExcretionJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedRenal Insufficiency | Chronic Kidney Disease | HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedA Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisRenal Insufficiency | Chronic Kidney Disease | HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedChronic Renal Failure Patients With Hyperphosphataemia Receiving HemodialysisJapan